Sugi Predict

Sugi Predict / Compounds / SCHEMBL1734009

SCHEMBL1734009

SCHEMBL1734009

CCCCC(CNC(=O)OCc1ccccc1)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSL P07711 1/20 0.56
▸ CTSS P25774 1/20 0.56
▸ SLC1A3 P43003 1/20 0.54
▸ SLC1A1 P43005 1/20 0.54
▸ SYK P43405 1/20 0.52
▸ HTT P42858 1/20 0.50
▸ SIRT2 Q8IXJ6 1/20 0.49
▸ SIRT1 Q96EB6 1/20 0.49
▸ SMN1; SMN2 Q16637 3/20 0.49
▸ LMNA P02545 2/20 0.49
▸ MME P08473 1/20 0.48
▸ ECE1 P42892 1/20 0.48
▸ NPC1 O15118 2/20 0.48
▸ RAB9A P51151 2/20 0.48
▸ FOLH1 Q04609 2/20 0.47
▸ HSD17B10 Q99714 2/20 0.46
▸ CTSK P43235 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ PTGES O14684 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3319289 1.00 CTSL (0.56) CTSLCTSSSLC1A3SLC1A1SYK
SCHEMBL133032 0.96 SIRT2 (0.53) CTSLCTSSSLC1A3SLC1A1SYK
SCHEMBL3902571 0.96 SIRT2 (0.53) CTSLCTSSSLC1A3SLC1A1SYK
SCHEMBL13434967 0.96 SIRT2 (0.53) CTSLCTSSSLC1A3SLC1A1SYK
SCHEMBL8054994 0.95 SIRT2 (0.55) CTSLCTSSSLC1A3SLC1A1SYK
SCHEMBL22648528 0.92 SLC1A3 (0.56) CTSLCTSSSLC1A3SLC1A1SYK
SCHEMBL15109512 0.85 CTSL (0.57) CTSLCTSSSLC1A3SLC1A1SYK
SCHEMBL18085401 0.85 CTSL (0.57) CTSLCTSSSYKHTTSIRT2
SCHEMBL14996273 0.85 CTSL (0.57) CTSLCTSSSLC1A3SLC1A1SYK
SCHEMBL17865359 0.85 SLC1A3 (0.55) CTSLCTSSSLC1A3SLC1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105753726-B Preparation method for asymmetrically synthesizing pregabalin 深圳市华先医药科技有限公司 2020-11-10 — — CN disclosed
EP-1896452-B1 N-FORMYL HYDROXYLAMINE COMPOUNDS NOVARTIS AG (CH) 2011-11-16 — — EP disclosed
US-8044199-B2 N-formyl hydroxylamines compounds VICURON HOLDINGS LLC (US) 2011-10-25 — — US disclosed
US-20100125075-A1 Antibacterial Agents BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) 2010-05-20 — — US disclosed
US-20100063278-A1 N-Formyl Hydroxylamines compounds NOVARTIS AG (CH) 2010-03-11 — — US disclosed
US-20090318445-A1 PDF INHIBITORS NORVARTIS AG (CH) 2009-12-24 — — US disclosed
US-7615635-B2 N-formyl hydroxylamines NOVARTIS AG (CH) 2009-11-10 — — US disclosed
US-7612059-B2 Pyrrolidine bicyclic compounds and its derivatives, compositions and methods of use VICURON PHARMACEUTICALS, INC. (US) 2009-11-03 — — US disclosed
US-20090149509-A1 NOVEL PYRROLIDINE BICYCLIC COMPOUNDS AND ITS DERIVATIVES, COMPOSITIONS AND METHODS OF USE VICURON PHARMACEUTICALS INC. (US) 2009-06-11 — — US disclosed
US-20090069322-A1 N-FORMYL HYDROXYLAMINE DERIVATIVES AS INHIBITORS OF BACTERIAL POLYPEPTIDE FORMYLASE FOR TREATING MICROBIAL INFECTIONS BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) 2009-03-12 — — US disclosed
WO-2002041886-A1 YDROXAMIC ACID OR N-FORMYL HYDROXYLAMINE DERIVATIVES AS INHIBITORS OF BAKTERIAL POLYPEPTIDE DEFORMYLASE FOR TREATING MICROBIAL INFECTIONS BRITISH BIOTECH PHARMACEUTICALS LTD (GB) 2002-05-30 — — WO disclosed
EP-1202968-A2 ANTIBACTERIAL AGENTS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 2002-05-08 — — EP disclosed
EP-1169031-A1 ANTIMICROBIAL AGENTS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 2002-01-09 — — EP disclosed
EP-1165532-A1 ANTIBACTERIAL AGENTS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 2002-01-02 — — EP disclosed
WO-2001010834-A9 ANTIBACTERIAL AGENTS BRITISH BIOTECH PHARM (GB) 2001-08-09 — — WO disclosed
WO-2001010834-A2 ANTIBACTERIAL AGENTS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 2001-02-15 — — WO disclosed
EP-1052984-A1 ANTIBACTERIAL AGENTS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 2000-11-22 — — EP disclosed
WO-2000061134-A1 ANTIMICROBIAL AGENTS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 2000-10-19 — — WO disclosed
WO-2000058294-A1 ANTIBACTERIAL AGENTS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 2000-10-05 — — WO disclosed
WO-1999039704-A1 ANTIBACTERIAL AGENTS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1999-08-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069322-A1 N-FORMYL HYDROXYLAMINE DERIVATIVES AS INHIBITORS OF BACTERIAL POLYPEPTIDE FORMYLASE FOR TREATING MICROBIAL INFECTIONS FPR1, FPR3, FPR2 CTSL 206/4885CTSS 670/4885SLC1A3 2967/4885
US-20100063278-A1 N-Formyl Hydroxylamines compounds PDF, MMP2, HNMT CTSL 140/4885CTSS 84/4885SLC1A3 3131/4885
US-20090318445-A1 PDF INHIBITORS PDF, TIMP3, MMP2 CTSL 39/4885CTSS 50/4885SLC1A3 3794/4885
US-20100125075-A1 Antibacterial Agents NQO2, DAO, Q6ZSR9 CTSL 330/4885CTSS 749/4885SLC1A3 2689/4885
US-20090149509-A1 NOVEL PYRROLIDINE BICYCLIC COMPOUNDS AND ITS DERIVATIVES, COMPOSITIONS AND METHODS OF USE PDF, PNPO, PDXK CTSL 550/4885CTSS 1421/4885SLC1A3 3607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.